Phosphatidylinositol 3-Kinase p85α Subunit-Dependent Interaction with BCR/ABL-Related Fusion Tyrosine Kinases: Molecular Mechanisms and Biological Consequences

REFERENCES

• Amarante-Mendes, G. P., T. Jascur, W. K. Nishioka, T. Mustelin, and D. R. Green. 1997. Bcr-Abl-mediated resistance to apoptosis is independent of PI 3-kinase activity. Cell Death Differ. 4:548–554.
   PubMedGoogle Scholar
• Bai, R. Y., T. Ouyang, C. Miething, S. W. Morris, C. Peschel, and J. Duyster. 2000. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 96:4319–4327.
   PubMed Web of Science ®Google Scholar
• Bassermann, F., T. Jahn, C. Miething, P. Seipel, R. Y. Bai, S. Coutinho, V. L. Tybulewicz, C. Peschel, and J. Duyster. 2002. Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway. J. Biol. Chem. 277:12437–12445. [Online.]
   PubMedGoogle Scholar
• Blume-Jensen, P., and T. Hunter. 2001. Oncogenic kinase signalling. Nature 411:355–365.
   PubMed Web of Science ®Google Scholar
• Booker, G. W., I. Gout, A. K. Downing, P. C. Driscoll, J. Boyd, M. D. Waterfield, and I. D. Campbell. 1993. Solution structure and ligand-binding site of the SH3 domain of the p85 alpha subunit of phosphatidylinositol 3-kinase. Cell 73:813–822.
   PubMedGoogle Scholar
• Calabretta, B., and T. Skorski. 1996. BCR/ABL regulation of PI-3 kinase activity. Leuk. Lymphoma 23:473–476.
   PubMed Web of Science ®Google Scholar
• Cantley, L. C. 2002. The phosphoinositide 3-kinase pathway. Science 296:1655–1657.
   PubMed Web of Science ®Google Scholar
• Carroll, M., M. H. Tomasson, G. F. Barker, T. R. Golub, and D. G. Gilliland. 1996. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc. Natl. Acad. Sci. USA 93:14845–14850.
   PubMed Web of Science ®Google Scholar
• Chang, F., J. T. Lee, P. M. Navolanic, L. S. Steelman, J. G. Shelton, W. L. Blalock, R. A. Franklin, and J. A. McCubrey. 2003. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17:590–603.
   PubMed Web of Science ®Google Scholar
• Cross, N. C., and A. Reiter. 2002. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia 16:1207–1212.
   PubMed Web of Science ®Google Scholar
• Crouin, C., M. Arnaud, F. Gesbert, J. Camonis, and J. Bertoglio. 2001. A yeast two-hybrid study of human p97/Gab2 interactions with its SH2 domain-containing binding partners. FEBS Lett. 495:148–153.
   PubMedGoogle Scholar
• Davies, S. P., H. Reddy, M. Caivano, and P. Cohen. 2000. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351:95–105.
   PubMed Web of Science ®Google Scholar
• Dhand, R., K. Hara, I. Hiles, B. Bax, I. Gout, G. Panayotou, M. J. Fry, K. Yonezawa, M. Kasuga, and M. D. Waterfield. 1994. PI 3-kinase: structural and functional analysis of intersubunit interactions. EMBO J. 13:511–521.
   PubMedGoogle Scholar
• Dierov, J., Q. Xu, R. Dierova, and M. Carroll. 2002. TEL/platelet-derived growth factor receptor beta activates phosphatidylinositol 3 (PI3) kinase and requires PI3 kinase to regulate the cell cycle. Blood 99:1758–1765.
   PubMedGoogle Scholar
• Gesbert, F., W. R. Sellers, S. Signoretti, M. Loda, and J. D. Griffin. 2000. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-kinase/AKT pathway. J. Biol. Chem. 275:39223–39230.
   PubMed Web of Science ®Google Scholar
• Greenland, C., C. Touriol, G. Chevillard, S. W. Morris, R. Bai, J. Duyster, G. Delsol, and M. Allouche. 2001. Expression of the oncogenic NPM-ALK chimeric protein in human lymphoid T-cells inhibits drug-induced, but not Fas-induced apoptosis. Oncogene 20:7386–7397.
   PubMed Web of Science ®Google Scholar
• Griffin, J. D. 2001. Phosphatidyl inositol signaling by BCR/ABL: opportunities for drug development. Cancer Chemother. Pharmacol. 48:S11–S16.
   PubMed Web of Science ®Google Scholar
• Gu, H., K. Saito, L. D. Klaman, J. Shen, T. Fleming, Y. Wang, J. C. Pratt, G. Lin, B. Lim, J. P. Kinet, and B. G. Neel. 2001. Essential role for Gab2 in the allergic response. Nature 412:186–190.
   PubMed Web of Science ®Google Scholar
• Harrison-Findik, D., M. Susa, and L. Varticovski. 1995. Association of phosphatidylinositol 3-kinase with SHC in chronic myelogeneous leukemia cells. Oncogene 10:1385–1391.
   PubMedGoogle Scholar
• Hellyer, N. J., K. Cheng, and J. G. Koland. 1998. ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochem. J. 333:757–763.
   PubMed Web of Science ®Google Scholar
• Hiles, I. D., M. Otsu, S. Volinia, M. J. Fry, I. Gout, R. Dhand, G. Panayotou, F. Ruiz-Larrea, A. Thompson, N. F. Totty, et al. 1992. Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit. Cell 70:419–429.
   PubMed Web of Science ®Google Scholar
• Jain, S. K., W. Y. Langdon, and L. Varticovski. 1997. Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase. Oncogene 14:2217–2228.
   PubMedGoogle Scholar
• Jain, S. K., M. Susa, M. L. Keeler, N. Carlesso, B. Druker, and L. Varticovski. 1996. PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl. Blood 88:1542–1550.
   PubMed Web of Science ®Google Scholar
• Kharas, M. G., J. A. Deane, S. Wong, K. R. O'Bosky, N. Rosenberg, O. N. Witte, and D. A. Fruman. 2004. Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood 103:4268–4275. [Online.]
   PubMed Web of Science ®Google Scholar
• Kharas, M. G., and D. A. Fruman. 2005. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res. 65:2047–2053.
   PubMed Web of Science ®Google Scholar
• Klejman, A., L. Rushen, A. Morrione, A. Slupianek, and T. Skorski. 2002. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene 21:5868–5876.
   PubMed Web of Science ®Google Scholar
• Klippel, A., J. A. Escobedo, Q. Hu, and L. T. Williams. 1993. A region of the 85-kilodalton (kDa) subunit of phosphatidylinositol 3-kinase binds the 110-kDa catalytic subunit in vivo. Mol. Cell. Biol. 13:5560–5566.
   PubMedGoogle Scholar
• Kolibaba, K. S., and B. J. Druker. 1997. Protein tyrosine kinases and cancer. Biochim. Biophys. Acta 1333:F217–F248.
   PubMed Web of Science ®Google Scholar
• Koyama, S., H. Yu, D. C. Dalgarno, T. B. Shin, L. D. Zydowsky, and S. L. Schreiber. 1993. Structure of the PI3K SH3 domain and analysis of the SH3 family. Cell 72:945–952.
   PubMedGoogle Scholar
• Liang, J., J. K. Chen, S. T. Schreiber, and J. Clardy. 1996. Crystal structure of P13K SH3 domain at 20 angstroms resolution. J. Mol. Biol. 257:632–643.
   PubMedGoogle Scholar
• Majewski, M., M. Nieborowska-Skorska, P. Salomoni, A. Slupianek, K. Reiss, R. Trotta, B. Calabretta, and T. Skorski. 1999. Activation of mitochondrial Raf-1 is involved in the antiapoptotic effects of Akt. Cancer Res. 59:2815–2819.
   PubMed Web of Science ®Google Scholar
• Marley, S. B., J. L. Lewis, H. Schneider, C. E. Rudd, and M. Y. Gordon. 2004. Phosphatidylinositol-3 kinase inhibitors reproduce the selective antiproliferative effects of imatinib on chronic myeloid leukaemia progenitor cells. Br. J. Haematol. 125:500–511.
   PubMed Web of Science ®Google Scholar
• Mayer, B. J., P. K. Jackson, R. A. Van Etten, and D. Baltimore. 1992. Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo. Mol. Cell. Biol. 12:609–618.
   PubMedGoogle Scholar
• McGlade, C. J., C. Ellis, M. Reedijk, D. Anderson, G. Mbamalu, A. D. Reith, G. Panayotou, P. End, A. Bernstein, A. Kazlauskas, et al. 1992. SH2 domains of the p85 alpha subunit of phosphatidylinositol 3-kinase regulate binding to growth factor receptors. Mol. Cell. Biol. 12:991–997.
   PubMed Web of Science ®Google Scholar
• Muller, A. J., A. M. Pendergast, M. H. Havlik, L. Puil, T. Pawson, and O. N. Witte. 1992. A limited set of SH2 domains binds BCR through a high-affinity phosphotyrosine-independent interaction. Mol. Cell. Biol. 12:5087–5093.
   PubMed Web of Science ®Google Scholar
• Neshat, M. S., A. B. Raitano, H. G. Wang, J. C. Reed, and C. L. Sawyers. 2000. The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol. Cell. Biol. 20:1179–1186.
   PubMed Web of Science ®Google Scholar
• Nguyen, M. H., J. M. Ho, B. K. Beattie, and D. L. Barber. 2001. TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3′-kinase/protein kinase B signaling pathway. J. Biol. Chem. 276:32704–32713. [Online.]
   PubMedGoogle Scholar
• Nieborowska-Skorska, M., G. Hoser, P. Kossev, M. A. Wasik, and T. Skorski. 2002. Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis. Blood 99:4531–4539.
   PubMed Web of Science ®Google Scholar
• Nieborowska-Skorska, M., M. A. Wasik, A. Slupianek, P. Salomoni, T. Kitamura, B. Calabretta, and T. Skorski. 1999. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J. Exp. Med. 189:1229–1242.
   PubMed Web of Science ®Google Scholar
• Okuda, K., T. R. Golub, D. G. Gilliland, and J. D. Griffin. 1996. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene 13:1147–1152.
   PubMedGoogle Scholar
• Otsu, M., I. Hiles, I. Gout, M. J. Fry, F. Ruiz-Larrea, G. Panayotou, A. Thompson, R. Dhand, J. Hsuan, N. Totty, et al. 1991. Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase. Cell 65:91–104.
   PubMed Web of Science ®Google Scholar
• Sattler, M., and J. D. Griffin. 2003. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin. Hematol. 40:4–10.
   PubMed Web of Science ®Google Scholar
• Sattler, M., M. G. Mohi, Y. B. Pride, L. R. Quinnan, N. A. Malouf, K. Podar, F. Gesbert, H. Iwasaki, S. Li, R. A. Van Etten, H. Gu, J. D. Griffin, and B. G. Neel. 2002. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 1:479–492.
   PubMed Web of Science ®Google Scholar
• Sattler, M., R. Salgia, K. Okuda, N. Uemura, M. A. Durstin, E. Pisick, G. Xu, J. L. Li, K. V. Prasad, and J. D. Griffin. 1996. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3′ kinase pathway. Oncogene 12:839–846.
   PubMed Web of Science ®Google Scholar
• Sattler, M., R. Salgia, G. Shrikhande, S. Verma, E. Pisick, K. V. Prasad, and J. D. Griffin. 1997. Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a complex containing c-kit, phosphatidylinositol 3-kinase, and p120(CBL). J. Biol. Chem. 272:10248–10253.
   PubMed Web of Science ®Google Scholar
• Scheid, M. P., P. A. Marignani, and J. R. Woodgett. 2002. Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B. Mol. Cell. Biol. 22:6247–6260.
   PubMed Web of Science ®Google Scholar
• Skorski, T. 2002. Oncogenic tyrosine kinases and the DNA-damage response. Nat. Rev. Cancer 2:351–360.
   PubMed Web of Science ®Google Scholar
• Skorski, T., A. Bellacosa, M. Nieborowska-Skorska, M. Majewski, R. Martinez, J. K. Choi, R. Trotta, P. Wlodarski, D. Perrotti, T. O. Chan, M. A. Wasik, P. N. Tsichlis, and B. Calabretta. 1997. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 16:6151–6161.
   PubMed Web of Science ®Google Scholar
• Skorski, T., P. Kanakaraj, D. H. Ku, M. Nieborowska-Skorska, E. Canaani, G. Zon, B. Perussia, and B. Calabretta. 1994. Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth. J. Exp. Med. 179:1855–1865.
   PubMed Web of Science ®Google Scholar
• Skorski, T., P. Kanakaraj, M. Nieborowska-Skorska, M. Z. Ratajczak, S. C. Wen, G. Zon, A. M. Gewirtz, B. Perussia, and B. Calabretta. 1995. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 86:726–736.
   PubMed Web of Science ®Google Scholar
• Skorski, T., M. Nieborowska-Skorska, P. Wlodarski, M. Wasik, R. Trotta, P. Kanakaraj, P. Salomoni, M. Antonyak, R. Martinez, M. Majewski, A. Wong, B. Perussia, and B. Calabretta. 1998. The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing. Blood 91:406–418.
   PubMedGoogle Scholar
• Slupianek, A., G. Hoser, I. Majsterek, A. Bronisz, M. Malecki, J. Blasiak, R. Fishel, and T. Skorski. 2002. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G2/M phase, and protection from apoptosis. Mol. Cell. Biol. 22:4189–4201.
   PubMed Web of Science ®Google Scholar
• Slupianek, A., M. Nieborowska-Skorska, G. Hoser, A. Morrione, M. Majewski, L. Xue, S. W. Morris, M. A. Wasik, and T. Skorski. 2001. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res. 61:2194–2199.
   PubMed Web of Science ®Google Scholar
• Slupianek, A., and T. Skorski. 2004. NPM/ALK downregulates p27(Kip1) in a PI-3K-dependent manner. Exp. Hematol. 32:1265–1271.
   PubMed Web of Science ®Google Scholar
• Vivanco, I., and C. L. Sawyers. 2002. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2:489–501.
   PubMed Web of Science ®Google Scholar
• Waksman, G., S. E. Shoelson, N. Pant, D. Cowburn, and J. Kuriyan. 1993. Binding of a high affinity phosphotyrosyl peptide to the Src SH2 domain: crystal structures of the complexed and peptide-free forms. Cell 72:779–790.
   PubMed Web of Science ®Google Scholar
• Weng, Z., R. J. Rickles, S. Feng, S. Richard, A. S. Shaw, S. L. Schreiber, and J. S. Brugge. 1995. Structure-function analysis of SH3 domains: SH3 binding specificity altered by single amino acid substitutions. Mol. Cell. Biol. 15:5627–5634.
   PubMed Web of Science ®Google Scholar
• Yu, H., J. K. Chen, S. Feng, D. C. Dalgarno, A. W. Brauer, and S. L. Schreiber. 1994. Structural basis for the binding of proline-rich peptides to SH3 domains. Cell 76:933–945.
   PubMed Web of Science ®Google Scholar
• Zou, X., and K. Calame. 1999. Signaling pathways activated by oncogenic forms of Abl tyrosine kinase. J. Biol. Chem. 274:18141–18144.
   PubMed Web of Science ®Google Scholar